AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
INVO Fertility Announces 1:3 Reverse Stock Split Effective July 21, 2025.
ByAinvest
Monday, Jul 21, 2025 4:33 pm ET1min read
INVO Fertility will effect a 1-for-3 reverse stock split effective July 21, 2025, at 12:01 a.m. Eastern Time. The company's common stock will trade on Nasdaq under the same symbol, "IVF," but with a new CUSIP number, 44984F708. Every 3 shares of issued and outstanding common stock will be exchanged for 1 share. The change aims to increase the company's stock price and improve its marketability.
INVO Fertility, Inc. (NASDAQ: IVF) has announced a 1-for-3 reverse stock split effective July 21, 2025, at 12:01 a.m. Eastern Time. The reverse stock split aims to increase the company's stock price and improve its marketability. As a result of the split, every 3 shares of issued and outstanding common stock will be exchanged for 1 share, with any fractional shares being rounded up to the next higher whole share.Following the reverse stock split, the company's common stock will trade on Nasdaq under the same symbol, "IVF," but with a new CUSIP number, 44984F708. Immediately after the reverse stock split becomes effective, INVO Fertility will have approximately 928,272 shares of common stock issued and outstanding. Additionally, the company's authorized shares of common stock will be adjusted proportionately to 1,388,888 shares.
The reverse stock split is primarily intended to bring INVO Fertility into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing. However, no assurance can be given that such a reverse stock split will enable the company to regain compliance with the Nasdaq minimum bid price requirement.
INVO Fertility is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. The company's principal commercial strategy focuses on building, acquiring, and operating fertility clinics, including "INVO Centers" dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell® medical device. The IVC procedure provides patients with a more natural, intimate, and affordable experience compared to other ART treatments.
For more information, please visit www.invofertility.com.
References:
[1] https://finance.yahoo.com/news/invo-fertility-announces-1-3-120000298.html
[2] https://www.globenewswire.com/news-release/2025/07/17/3117139/0/en/INVO-Fertility-Announces-a-1-3-Reverse-Stock-Split-Effective-Pre-Market-Opening-on-July-21-2025.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet